Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH -Mutant Gliomas
Open accessPublished version of a preprint
Abstract
Purpose: Isocitrate dehydrogenase (IDH) gene mutations occur in low-grade and high-grade gliomas. We sought to identify the genetic basis of malignant phenotype heterogeneity in IDH-mutant gliomas. Methods: We prospectively implanted tumor specimens from 20 consecutive IDH1-mutant glioma resections into mouse brains and genotyped all resection specimens using a CLIA-certified molecular panel. Gliomas with cancer driver mutations were tested for sensitivity to targeted inhibitors in vitro. Associations between genomic alterations and outcomes were analyzed in patients. Results: By 10 months, 8 of 20 IDH1-mutant gliomas developed intracerebral xenografts. All xenografts maintained mutant IDH1 and high levels of 2-hydroxyglutarate on serial transplantation. All xenograft-producing gliomas harbored “lineage-defining” mutations in CIC (oligodendroglioma) or TP53 (astrocytoma), and 6 of 8 additionally had activating mutations in PIK3CA or amplification of PDGFRA, MET, or N-MYC. Only IDH1 and CIC/TP53 mutations were detected in non–xenograft-forming gliomas (P = 0.0007). Targeted inhibition of the additional alterations decreased proliferation in vitro. Moreover, we detected alterations in known cancer driver genes in 13.4% of IDH-mutant glioma patients, including PIK3CA, KRAS, AKT, or PTEN mutation or PDGFRA, MET, or N-MYC amplification. IDH/CIC mutant tumors were associated with PIK3CA/KRAS mutations whereas IDH/TP53 tumors correlated with PDGFRA/MET amplification. Presence of driver alterations at progression was associated with shorter subsequent progression-free survival (median 9.0 vs. 36.1 months; P = 0.0011). Conclusion: A subset of IDH-mutant gliomas with mutations in driver oncogenes has a more malignant phenotype in patients. Identification of these alterations may provide an opportunity for use of targeted therapies in these patients. Clin Cancer Res; 20(11); 2898–909. ©2014 AACR.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IDH1 mutations are early events in glial cancer development, raising the possibility that additional oncogenic mutations render GBM tumors less dependent on mutant IDH for proliferation and progression.
“IDH1 mutations are early events in the development of glial cancer (Watanabe et al., 2009), raising the possibility that IDH mutations are important for tumor initiation, but accumulation of additional oncogenic mutations renders GBM tumors less dependent on constitutive expression of mutant IDH for tumor proliferation and progression (Johnson et al., 2014; Wakimoto et al., 2014).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Wakimoto et al., 2014
Network analysis connects oncogenic RAS to several mutated driver genes-KMT2D, PIK3CA, PTEN, and IDH1-that control signaling and metabolic pathways in KRAS-driven cancers.
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [140]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · see citing works
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works
<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,814 · see citing works
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,820 · see citing works
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974 · see citing works
The multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,858 · see citing works
Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368 · see citing works
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362 · see citing works
van den Bent, M. J., Brandes, A. A., TAPHOORN, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J., Bernsen, H. J. J. A., Frénay, M., Tijssen, C. C., Grisold, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,220 · see citing works
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163 · see citing works
Cairncross, G. J., Wang, M., Shaw, E., Jenkins, R. B., Brachman, D. G., Buckner, J. C., Fink, K., Souhami, L., Laperrière, N., Curran, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,152 · see citing works
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036 · see citing works
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027 · see citing works
Hartmann, C. J., Hentschel, B., Wick, W., Capper, D., Felsberg, J., Simon, M., Westphal, M., Schackert, G., Meyermann, R., Pietsch, T., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0781-z · Cited by 823 · see citing works
Isolation of cancer stem cells from adult glioblastoma multiforme
Yuan, X., Curtin, J. F., Xiong, Y., Liu, G., Wachsmann‐Hogiu, S., Farkas, D. L., Black, K. L., & Yu, J. S. (2004) · Oncogene · doi:10.1038/sj.onc.1208311 · Cited by 798 · see citing works
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0715 · Cited by 707 · see citing works
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655 · see citing works
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D., & Collins, V. P. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-025 · Cited by 593 · see citing works
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodríguez, F. J., Rosemberg, S., Oba‐Shinjo, S. M., Marie, S. K. N., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584 · see citing works
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodríguez, F. J., Cahill, D. P., McLendon, R. E., Riggins, G. J., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 545 · see citing works
Self-citationIDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K., Guillevin, R., Laffaire, J., Paris, S., Boisselier, B., Idbaïh, A., Laigle–Donadey, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f96282 · Cited by 532 · see citing works
Yan, H., Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H. S., Gallia, G. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.18 · Cited by 530 · see citing works
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
Capper, D., Weißert, S., Balß, J., Habel, A., Meyer, J., Jaeger, D., Ackermann, U., Tessmer, C., Korshunov, A., Zentgraf, H., et al. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00352.x · Cited by 523 · see citing works
Furet, P., Guagnano, V., Fairhurst, R. A., Imbach, P. A., Bruce, I., Knapp, M. S., Fritsch, C. M., Blasco, F., Blanz, J., Aichholz, R., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.007 · Cited by 492 · see citing works
Lai, A., Kharbanda, S., Pope, W. B., Tran, A. N., Solis, O. E., Peale, F. V., Jr., Forrest, W. F., Pujara, K., Carrillo, J., Pandita, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8715 · Cited by 432 · see citing works
Hunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J. W., Greenman, C., Edkins, S., Bignell, G. R., Davies, H. R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0127 · Cited by 431 · see citing works
Self-citationDias-Santagata, D. C., Akhavanfard, S., David, S. S., Vernovsky, K., Kuhlmann, G., Boisvert, S. L., Stubbs, H., McDermott, U., Settleman, J. E., Kwak, E. L., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000070 · Cited by 392 · see citing works
Self-citationReductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells
Fendt, S.-M., Bell, E. L., Keibler, M. A., Olenchock, B. A., Mayers, J. R., Wasylenko, T. M., Vokes, N. I., Guarente, L., Heiden, M. G. V., & Stephanopoulos, G. (2013) · Nature Communications · doi:10.1038/ncomms3236 · Cited by 364 · see citing works
Self-citationWakimoto, H., Kesari, S., Farrell, C. J., Curry, W. T., Zaupa, C., Aghi, M. K., Kuroda, T., Stemmer-Rachamimov, A. O., Shah, K., Liu, T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3886 · Cited by 361 · see citing works
Self-citationMutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas
Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y., Cummins, J. M., McLendon, R. E., Fults, D. W., Velculescu, V. E., Bigner, D. D., & Yan, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1170 · Cited by 336 · see citing works
Yip, S. S. F., Butterfield, Y. S. N., Morozova, O., Chittaranjan, S., Blough, M. D., An, J., Birol, İ., Chesnelong, C., Chiu, R., Chuah, E., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2995 · Cited by 307 · see citing works
Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K. S., Inagaki, A., Silber, J., Gorovets, D. J., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H. J., Chan, T. A.-T., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 277 · see citing works
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells
Wakimoto, H., Mohapatra, G., Kanai, R., Curry, W. T., Yip, S. S. F., Nitta, M., Patel, A. P., Barnard, Z. R., Stemmer-Rachamimov, A. O., Louis, D. N., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor195 · Cited by 239 · see citing works
Self-citationJoo, K. M., Kim, J., Jin, J., Kim, M., Seol, H. J., Muradov, J. M., Yang, H., Choi, Y., Park, W., Kong, D., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.013 · Cited by 230 · see citing works
Self-citationFendt, S., Bell, E. L., Keibler, M. A., Davidson, S. M., Wirth, G. J., Fiske, B. P., Mayers, J. R., Schwab, M. G., Bellinger, G., Csibi, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0080 · Cited by 196 · see citing works
Self-citationAn in vivo patient-derived model of endogenous IDH1-mutant glioma
Luchman, H. A., Stechishin, O. D. M., Dang, N. H., Blough, M. D., Chesnelong, C., Kelly, J. J., Nguyen, S. A., Chan, J. A.-W., Weljie, A. M., Cairncross, J. G., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor207 · Cited by 194 · see citing works
Chen, C., Liu, Y., Lü, C., Cross, J. R., Morris, J. P., Shroff, A., Ward, P. S., Bradner, J. E., Thompson, C. B., & Lowe, S. W. (2013) · Genes & Development · doi:10.1101/gad.226613.113 · Cited by 182 · see citing works
Perry, A., Miller, C. R., Gujrati, M., Scheithauer, B. W., Casavilca-Zambrano, S. A., Jost, S. C., Raghavan, R., Qian, J., Cochran, E. J., Huse, J. T., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00167.x · Cited by 177 · see citing works
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas
Knobbe-Thomsen, C. B., REIFENBERGER, J., & Reifenberger, G. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0929-9 · Cited by 156 · see citing works
Mutant Metabolic Enzymes Are at the Origin of Gliomas
Yan, H., Bigner, D. D., Velculescu, V. E., & Parsons, D. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2650 · Cited by 153 · see citing works
Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, G., Reitman, Z. J., Duncan, C. G., Spasojević, I., Gooden, D. M., Rasheed, B. A., Yang, R. R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 124 · see citing works
Jeuken, J. W. M., den Broecke, C. V., Gijsen, S. J., Boots‐Sprenger, S., & Wesseling, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0239-0 · Cited by 111 · see citing works
Phillips, J. J., Aranda, D., Ellison, D. W., Judkins, A. R., Croul, S. E., Brat, D. J., Ligon, K. L., Horbinski, C., Venneti, S., Zadeh, G. M., et al. (2013) · Brain Pathology · doi:10.1111/bpa.12043 · Cited by 108 · see citing works
Oligodendroglioma cell lines containing t(1;19)(q10;p10)
Kelly, J. J., Blough, M. D., Stechishin, O. D. M., Chan, J. A.-W., Beauchamp, D. R., Perizzolo, M., Demetrick, D. J., Steele, L., Auer, R. N., Hader, W. J., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq031 · Cited by 94 · see citing works
Walker, E. J., Zhang, C., Castelo‐Branco, P., Hawkins, C. E., Wilson, W. V., Zhukova, N., Alon, N., Novokmet, A., Baskin, B., Ray, P. N., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2266 · Cited by 63 · see citing works
Prospective, high-throughput molecular profiling of human gliomas
Chi, A. S., Batchelor, T. T., Dias-Santagata, D. C., Borger, D. R., Stiles, C. D., Wang, D. L., Curry, W. T., Wen, P. Y., Ligon, K. L., Ellisen, L. W., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0938-9 · Cited by 51 · see citing works
Self-citationKlink, B., Miletić, H., Stieber, D., Huszthy, P. C., Valenzuela, J. A. C., Balß, J., Wang, J., Schubert, M., Sakariassen, P. Ø., Sundstrøm, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059773 · Cited by 44 · see citing works
Odia, Y., Orr, B. A., Bell, W. R., Eberhart, C. G., & Rodríguez, F. J. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1221-4 · Cited by 29 · see citing works
Burford, A., Little, S. E., Jury, A., Popov, S., Laxton, R. C., Doey, L. J., Al‐Sarraj, S., Jürgensmeier, J. M., & Jones, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071777 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · see citing works
Glioma Subclassifications and Their Clinical Significance
Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0519-x · Cited by 812 · see citing works
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Han, S., Liu, Y., Cai, S. J., Qian, M., Ding, J., Larion, M., Gilbert, M. R., & Yang, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0814-x · Cited by 661 · see citing works
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
Flynn, R. L., Cox, K. E., Jeitany, M., Wakimoto, H., Bryll, A. R., Ganem, N. J., Bersani, F., Pineda, J. R., Suvà, M. L., Benes, C. H., et al. (2015) · Science · doi:10.1126/science.1257216 · Cited by 504 · see citing works
Self-citationThe p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433 · see citing works
Self-citationHistone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
Chakraborty, A. A., Laukka, T., Myllykoski, M., Ringel, A. E., Booker, M. A., Tolstorukov, M. Y., Meng, Y. J., Meier, S. R., Jennings, R. B., Creech, A. L., et al. (2019) · Science · doi:10.1126/science.aaw1026 · Cited by 432 · see citing works
Patel, S. H., Poisson, L., Brat, D. J., Zhou, Y., Cooper, L., Snuderl, M., Thomas, C., Franceschi, A. M., Griffith, B. D., Flanders, A. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0560 · Cited by 426 · see citing works
Self-citationGritsch, S., Batchelor, T. T., & Castro, L. N. G. (2021) · Cancer · doi:10.1002/cncr.33918 · Cited by 380 · see citing works
Self-citationMcBrayer, S. K., Mayers, J. R., DiNatale, G. J., Shi, D. D., Khanal, J., Chakraborty, A. A., Sarosiek, K. A., Briggs, K. J., Robbins, A. K., Sewastianik, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.038 · Cited by 368 · see citing works
Self-citationBiological Role and Therapeutic Potential of IDH Mutations in Cancer
Waitkus, M. S., Diplas, B. H., & Yan, H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.011 · Cited by 334 · see citing works
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315 · see citing works
Isocitrate dehydrogenase mutations in gliomas
Waitkus, M. S., Diplas, B. H., & Yan, H. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov136 · Cited by 282 · see citing works
Núñez, F. J., Mendez, F., Kadiyala, P., Alghamri, M. S., Savelieff, M. G., Garcia-Fabiani, M. B., Haase, S., Koschmann, C. J., Calinescu, A., Kamran, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1427 · Cited by 257 · see citing works
Miller, J. J., Castro, L. N. G., McBrayer, S. K., Weller, M., Cloughesy, T. F., Portnow, J., Andronesi, O. C., Barnholtz‐Sloan, J. S., Baumert, B. G., Berger, M. S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac207 · Cited by 253 · see citing works
Self-citationIDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220 · see citing works
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
Pusch, S., Krausert, S., Fischer, V., Balß, J., Ott, M., Schrimpf, D., Capper, D., Sahm, F., Eisel, J., Beck, A.-C., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1677-y · Cited by 174 · see citing works
Myc-Driven glycolysis is a therapeutic target in glioblastoma
Tateishi, K., Iafrate, A. J., Ho, Q., Curry, W. T., Batchelor, T. T., Flaherty, K. T., Onozato, M. L., Lelic, N., Sundaram, S., Cahill, D. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2274 · Cited by 160 · see citing works
Self-citationGolebiewska, A., Hau, A., Oudin, A., Stieber, D., Yabo, Y. A., Baus, V., Barthelemy, V., Klein, E., Bougnaud, S., Keunen, O., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02226-7 · Cited by 159 · see citing works
Metabolic consequences of oncogenic IDH mutations
Parker, S. J., & Metallo, C. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.003 · Cited by 158 · see citing works
The molecular feature of macrophages in tumor immune microenvironment of glioma patients
Zhang, H., Luo, Y., Wu, W., Zhang, L., Wang, Z., Dai, Z., Feng, S., Cao, H., Cheng, Q., & Liu, Z. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.019 · Cited by 148 · see citing works
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1
Mazor, T., Chesnelong, C., Pankov, A., Jalbert, L. E., Hong, C., Hayes, J. L., Smirnov, I. V., Marshall, R. E., de Souza, C. F., Shen, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708914114 · Cited by 136 · see citing works
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Shi, D. D., Savani, M. R., Levitt, M. M., Wang, A. C., Endress, J. E., Bird, C. E., Buehler, J., Stopka, S. A., Regan, M. S., Lin, Y., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.011 · Cited by 135 · see citing works
Self-citationNew Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
Karsy, M. J., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0722-5 · Cited by 125 · see citing works
The Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 123 · see citing works
Higuchi, F., Nagashima, H., Ning, J., Koerner, M. V. A., Wakimoto, H., & Cahill, D. P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2000 · Cited by 121 · see citing works
Self-citationNing, J.-F., Stanciu, M., Humphrey, M. R., Gorham, J., Wakimoto, H., Nishihara, R., Lees, J. A., Zou, L., Martuza, R. L., Wakimoto, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10993-5 · Cited by 120 · see citing works
Self-citationManagement for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?
Tom, M. C., Cahill, D. P., Buckner, J. C., Dietrich, J., Parsons, M. W., & Yu, J. S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238353 · Cited by 104 · see citing works
Self-citationEstablishment of patient-derived organoid models of lower-grade glioma
Abdullah, K. G., Bird, C. E., Buehler, J., Gattie, L. C., Savani, M. R., Sternisha, A. C., Xiao, Y., Levitt, M. M., Hicks, W. H., Li, W., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab273 · Cited by 105 · see citing works
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Chen, R., Cohen, A. L., & Colman, H. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0418-0 · Cited by 103 · see citing works
Juratli, T. A., Stasik, S., Zolal, A., Schuster, C., Richter, S., Daubner, D., Juratli, M. A., Thowe, R., Hennig, S., Makina, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3717 · Cited by 105 · see citing works
IDH inhibition in gliomas: from preclinical models to clinical trials
Rudà, R., Horbinski, C., van den Bent, M. J., Preusser, M., & Soffietti, R. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00967-7 · Cited by 104 · see citing works
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity
Wu, M., Kondo, H., Kammula, A. V., Shi, L., Xiao, Y., Dhiab, S., Xu, Q., Slater, C. J., Avila, O. I., Merritt, J., et al. (2024) · Science · doi:10.1126/science.adl6173 · Cited by 103 · see citing works
Self-citationLan, F., Pan‐Hammarström, Q., Yu, H., & Yue, X. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13174 · Cited by 98 · see citing works
Tateishi, K., Higuchi, F., Miller, J. J., Koerner, M. V. A., Lelic, N., Shankar, G. M., Tanaka, S., Fisher, D. E., Batchelor, T. T., Iafrate, A. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2263 · Cited by 98 · see citing works
Self-citationSignaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 98 · see citing works
Self-citationTargeting IDH1-Mutated Malignancies with NRF2 Blockade
Liu, Y., Lu, Y., Celiku, O., Li, A., Wu, Q., Zhou, Y., & Yang, C. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy230 · Cited by 91 · see citing works
Nagashima, H., Lee, C. K., Tateishi, K., Higuchi, F., Subramanian, M. P., Rafferty, S., Melamed, L., Miller, J. J., Wakimoto, H., & Cahill, D. P. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0226 · Cited by 89 · see citing works
Self-citationSeker-Polat, F., Cingöz, A., Sur‐Erdem, İ., Ergüder, N., Erkent, A., Uyulur, F., Selvan, M. E., Gumus, Z. H., Gönen, M., Bayraktar, H., et al. (2019) · Cancers · doi:10.3390/cancers11111651 · Cited by 86 · see citing works
Self-citationMukherjee, J., Johannessen, T.-C. A., Ohba, S., Chow, T. T., Jones, L. E., Pandita, A., & Pieper, R. O. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2269 · Cited by 85 · see citing works
IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?
Kayabölen, A., Yilmaz, E., & Onder, T. B. (2021) · Biomedicines · doi:10.3390/biomedicines9070799 · Cited by 83 · see citing works
Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis
Appin, C., & Brat, D. J. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000048 · Cited by 82 · see citing works
Pre-clinical tumor models of primary brain tumors: Challenges and opportunities
Akter, F., Simon, B. G., de Boer, N. L., Redjal, N., Wakimoto, H., & Shah, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188458 · Cited by 80 · see citing works
Self-citationThe comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
Wang, H., Tang, K., Liang, T., Zhang, W., Li, J.-Y., Wang, W., Hu, H., Li, M., Wang, H., He, X.-Z., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0362-7 · Cited by 80 · see citing works
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Spino, M., Kurz, S. C., Chiriboga, L. A., Serrano, J., Zeck, B., Sen, N., Patel, S. V., Shen, G., Vasudevaraja, V., Tsirigos, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2312 · Cited by 79 · see citing works
Self-citationBiomarker-driven diagnosis of diffuse gliomas
Appin, C., & Brat, D. J. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.002 · Cited by 80 · see citing works
Modeling epigenetic lesions that cause gliomas
Rahme, G. J., Javed, N. M., Puorro, K. L., Xin, S., Hovestadt, V., Johnstone, S. E., & Bernstein, B. (2023) · Cell · doi:10.1016/j.cell.2023.06.022 · Cited by 73 · see citing works
Lan, F., YANG, Y., Han, J., Wu, Q., Yu, H., & Yue, X. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3271 · Cited by 71 · see citing works
HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
Jiang, Q., Braun, D. A., Clauser, K. R., Ramesh, V., Shirole, N. H., Duke-Cohan, J. E., Nabilsi, N., Kramer, N. J., Forman, C., Lippincott, I. E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.046 · Cited by 68 · see citing works
Batsios, G., Viswanath, P., Subramani, E., Najac, C., Gillespie, A. M., Santos, R. D., Molloy, A. R., Pieper, R. O., & Ronen, S. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-47021-x · Cited by 60 · see citing works
Accelerated progression of IDH mutant glioma after first recurrence
Miller, J. J., Loebel, F., Juratli, T. A., Tummala, S. S., Williams, E. A., Batchelor, T. T., Arrillaga‐Romany, I., & Cahill, D. P. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz016 · Cited by 60 · see citing works
Self-citationContemporary Mouse Models in Glioma Research
Hicks, W. H., Bird, C. E., Traylor, J. I., Shi, D. D., Ahmadieh, T. Y. E., Richardson, T. E., McBrayer, S. K., & Abdullah, K. G. (2021) · Cells · doi:10.3390/cells10030712 · Cited by 61 · see citing works
IDH mutation is associated with higher risk of malignant transformation in low-grade glioma
Leu, S., von Felten, S., Frank, S., Boulay, J., & Mariani, L. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2048-y · Cited by 59 · see citing works
Li, M., Kirtane, A. R., Kiyokawa, J., Nagashima, H., Lopes, A., Tirmizi, Z. A., Lee, C. K., Traverso, G., Cahill, D. P., & Wakimoto, H. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1094 · Cited by 59 · see citing works
Self-citationUpdates on the WHO diagnosis of IDH-mutant glioma
Reuß, D. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04250-5 · Cited by 59 · see citing works
The clinical use of IDH1 and IDH2 mutations in gliomas
Pïcca, A., Berzero, G., Stefano, A. L. D., & Sanson, M. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1548935 · Cited by 55 · see citing works
Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma
Morokoff, A. P., Ng, W., Gogos, A., & Kaye, A. H. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.02.008 · Cited by 54 · see citing works
Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers
Ichimura, K., Narita, Y., & Hawkins, C. E. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1439-7 · Cited by 54 · see citing works
Chen, R., Ravindra, V. M., Cohen, A. L., Jensen, R. L., Salzman, K. L., Prescot, A. P., & Colman, H. (2015) · Neurosurgical FOCUS · doi:10.3171/2015.1.focus14745 · Cited by 50 · see citing works
Zhang, N., Dai, Z., Wu, W., Wang, Z., Cao, H., Zhang, Y., Wang, Z., Zhang, H., & Cheng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656541 · Cited by 49 · see citing works
Gunn, K., Myllykoski, M., Cao, J. Z., Ahmed, M., Huang, B., Rouaisnel, B., Diplas, B. H., Levitt, M. M., Looper, R., Doench, J. G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0825 · Cited by 48 · see citing works
Tateishi, K., Nakamura, T., Juratli, T. A., Williams, E. A., Matsushita, Y., Miyake, S., Nishi, M., Miller, J. J., Tummala, S. S., Fink, A. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4144 · Cited by 48 · see citing works
Self-citationOlubiyi, O. I., Özdemir, A., Incekara, F., Tie, Y., Dolati, P., Hsu, L., Santagata, S., Chen, Z., Rigolo, L., & Golby, A. J. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.04.044 · Cited by 47 · see citing works
Higuchi, F., Fink, A. L., Kiyokawa, J., Miller, J. J., Koerner, M. V. A., Cahill, D. P., & Wakimoto, H. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0177 · Cited by 46 · see citing works
Self-citationRapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis
Richardson, T. E., Snuderl, M., Serrano, J., Karajannis, M. A., Heguy, A., Oliver, D., Raisanen, J. M., Maher, E. A., Pan, E., Barnett, S. L., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2431-y · Cited by 45 · see citing works
Unruh, D. J., Mirkov, S., Wray, B. D., Drumm, M. R., Lamano, J. B., Li, Y. D., Haider, Q. F., Javier, R., McCortney, K., Saratsis, A. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1222 · Cited by 44 · see citing works
Yue, X., Cao, D., Lan, F., Pan‐Hammarström, Q., Xia, T., & Yu, H. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now044 · Cited by 44 · see citing works
Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2
Liu, Y., Chou, F.-J., Lang, F., Zhang, M., Song, H., Zhang, W., Davis, D. L., Briceno, N., Zhang, Y., Cimino, P. J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3179 · Cited by 41 · see citing works
Esaki, S., Nigim, F., Moon, E., Luk, S. O., Kiyokawa, J., Curry, W. T., Cahill, D. P., Chi, A. S., Iafrate, A. J., Martuza, R. L., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30929 · Cited by 41 · see citing works
Self-citationIto, H., Watari, K., Shibata, T., Miyamoto, T., Murakami, Y., Nakahara, Y., Izumi, H., Wakimoto, H., Kuwano, M., Abé, T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0438 · Cited by 41 · see citing works
Self-citationGüllüoğlu, Ş., Tüysüz, E. C., Şahin, M., Kuşkucu, A., Yaltırık, C. K., Türe, U., Küçükkaraduman, B., Akbar, M. W., Gure, A. O., Bayrak, Ö. F., et al. (2018) · Brain Research · doi:10.1016/j.brainres.2018.08.035 · Cited by 38 · see citing works
Ballester, L. Y., Fuller, G. N., Powell, S. Z.-E., Sulman, E. P., Patel, K. P., Luthra, R., & Routbort, M. J. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw119 · Cited by 37 · see citing works
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
Sun, X., & Turcan, Ş. (2021) · Cells · doi:10.3390/cells10051225 · Cited by 37 · see citing works
Ensign, S. P. F., Jenkins, R. B., Giannini, C., Sarkaria, J. N., Galanis, E., & Kizilbash, S. H. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac205 · Cited by 38 · see citing works
Identification ofIDHandTERTpmutation status using1H‐MRS in 112 hemispheric diffuse gliomas
Öztürk-Işık, E., Cengiz, S. D., Özcan, A., Yakıcıer, C., Danyeli, A. E., Pamir, M. N., Özduman, K., & Di̇nçer, A. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26964 · Cited by 35 · see citing works
Li, M., Kirtane, A. R., Kiyokawa, J., Nagashima, H., Lopes, A., Tirmizi, Z. A., Lee, C. K., Traverso, G., Cahill, D. P., & Wakimoto, H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0525 · Cited by 35 · see citing works
Self-citationIDH-Mutant Low-grade Glioma: Advances in Molecular Diagnosis, Management, and Future Directions
Dono, A., Ballester, L. Y., Primdahl, D., Esquenazi, Y., & Bhatia, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01006-6 · Cited by 35 · see citing works
Hinrichs, B. H., Newman, S., Appin, C., Dunn, W. D., Cooper, L., Pauly, R., Kowalski, J., Rossi, M. R., & Brat, D. J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0270-7 · Cited by 34 · see citing works
Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma
Jones, L. E., Hilz, S., Grimmer, M., Mazor, T., Najac, C., Mukherjee, J., McKinney, A., Chow, T. T., Pieper, R. O., Ronen, S. M., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa088 · Cited by 31 · see citing works
Non-invasive assessment of telomere maintenance mechanisms in brain tumors
Viswanath, P., Batsios, G., Mukherjee, J., Gillespie, A. M., Larson, P. E. Z., Luchman, H. A., Phillips, J. J., Costello, J., Pieper, R. O., & Ronen, S. M. (2021) · Nature Communications · doi:10.1038/s41467-020-20312-y · Cited by 34 · see citing works
Mann, B., Artz, N., Darawsheh, R., Kram, D. E., Hingtgen, S., & Satterlee, A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00832-w · Cited by 33 · see citing works
Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors
Testa, U., Castelli, G., & Pelosi, E. (2018) · Medical Sciences · doi:10.3390/medsci6040085 · Cited by 30 · see citing works
Enigmas of IDH mutations in hematology/oncology
Heuser, M., Cruz, M. M. A., Goparaju, R., & Chaturvedi, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.005 · Cited by 28 · see citing works
Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts
Franceschi, E., Minichillo, S., & Brandes, A. A. (2017) · CNS Drugs · doi:10.1007/s40263-017-0454-8 · Cited by 29 · see citing works
CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition
Nasser, A. M., Melamed, L., Wetzel, E. A., Chang, J. C.-C., Nagashima, H., Kitagawa, Y., Muzyka, L., Wakimoto, H., Cahill, D. P., & Miller, J. J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0562 · Cited by 29 · see citing works
Self-citationSirtuin activation targets IDH-mutant tumors
Miller, J. J., Fink, A. L., Banagis, J. A., Nagashima, H., Subramanian, M. P., Lee, C. K., Melamed, L., Tummala, S. S., Tateishi, K., Wakimoto, H., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa180 · Cited by 28 · see citing works
Self-citationEstablishment and validation of an immune-based prognostic score model in glioblastoma
Qin, Z., Zhang, X., Chen, Z., & Liu, N. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106636 · Cited by 27 · see citing works
Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies
Waitkus, M. S., & Yan, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1827 · Cited by 26 · see citing works
Verheul, C., Ntafoulis, I., Kers, T. V., Hoogstrate, Y., Mastroberardino, P. G., Barnhoorn, S., Payán‐Gómez, C., Yen, R. T. C., Struys, E. A., Koolen, S. L. W., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab103 · Cited by 26 · see citing works
Liu, H., Xu, C., Diplas, B. H., Brown, A., Strickland, L. M., Yao, H., Ling, J., McLendon, R. E., Keir, S. T., Ashley, D. M., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad022 · Cited by 24 · see citing works
IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1α
Semukunzi, H., Roy, D., Li, H., Khan, G. J., Lyu, X., Yuan, S., & Lin, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.083 · Cited by 25 · see citing works
Infrequent RAS mutation is not associated with specific histological phenotype in gliomas
Makino, Y., Arakawa, Y., Yoshioka, E., Shofuda, T., Minamiguchi, S., Kawauchi, T., Tanji, M., Kanematsu, D., Nonaka, M., Okita, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08733-4 · Cited by 23 · see citing works
Ikegaki, N., & Shimada, H. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00312 · Cited by 23 · see citing works
Emerging approaches to target tumor metabolism
Ross, S. J., & Critchlow, S. E. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.07.001 · Cited by 21 · see citing works
Zhang, H., Zhang, N., Dai, Z., Wang, Z., Zhang, X., Liang, X., Zhang, L., Feng, S., Wu, W., Ye, W., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13315 · Cited by 20 · see citing works
ScreenFect A: an efficient and low toxic liposome for gene delivery to mesenchymal stem cells
Li, L., Ruan, G., Huang-Fu, M.-Y., Chen, Z., Liu, H.-N., Li, L. X., Hu, Y., Han, M. Y., Davidson, G. R., Levkin, P. A., et al. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.04.050 · Cited by 20 · see citing works
Role of molecular biomarkers in glioma resection: a systematic review
Li, L., Wang, Y., Li, Y., Fang, S., & Jiang, T. (2020) · Chinese Neurosurgical Journal · doi:10.1186/s41016-020-00198-x · Cited by 20 · see citing works
Savani, M. R., Shami, M. E., Miki, K., Gattie, L. C., Smith, B. C., Hicks, W. H., Weiss, J., Oken, S., Katta, L. N., Shipman, T. E., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf248 · Cited by 21 · see citing works
Brain tumor vessels—a barrier for drug delivery
Hempel, C., Johnsen, K. B., Kostrikov, S., Hamerlik, P., & Andresen, T. L. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09877-8 · Cited by 18 · see citing works
Faccion, R. S., Bernardo, P. S., Lopes, G. P. D. F., Bastos, L. S., Teixeira, C. L., de Oliveira, J. A., Fernandes, P. V., Dubois, L. G., Chimelli, L. M. C., & Maia, R. C. (2018) · Cellular Oncology · doi:10.1007/s13402-017-0361-5 · Cited by 18 · see citing works
- Authors
- Wakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., Dias-Santagata, D., Ellisen, L. W., Borger, D. R., Fendt, S.-M., Vander Heiden, M. G., Batchelor, T. T., Iafrate, A. J., Cahill, D. P., & Chi, A. S.
- Affiliations
- Harvard University (US)
- Authors' Affiliations: 1Department of Neurosurgery; 2Division of Hematology/Oncology, Department of Neurology, Stephen E. and Catherine Pappas Center for Neuro-Oncology, 3Translational Research Laboratory; 4Department of Pathology; 5Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; 6Translational Neuro-Oncology Laboratory; 7Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts; 8Vesalius Research Center, VIB and Department of Oncology, KU Leuven, Leuven, Belgium
- Corresponding author
- Cahill, Daniel P.
- Chi, Andrew S.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2014-05-29
- Volume
- 20
- Issue
- 11
- Pages
- 2898-2909
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC4070445
- OpenAlex
- W2137361994
- Cited by
- 190
- References
- 51
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 16 · 2023: 12 · 2022: 10 · 2021: 22 · 2020: 27 · 2019: 19 · 2018: 18 · 2017: 15 · 2016: 9 · 2015: 15 · 2014: 3
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- Wellcome Trust
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Cancer Institute (K24CA125440, P50CA165962)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- IDH-mutant glioma, IDH1 mutation, CIC mutation, TP53 mutation, PIK3CA mutation, KRAS mutation, PDGFRA amplification, MET amplification, MYCN amplification, 2-hydroxyglutarate, tumor xenografts, cancer driver mutations, targeted therapy, progression-free survival, oligodendroglioma, astrocytoma
- MeSH terms
- Animals, Brain Neoplasms, Cell Transformation, Neoplastic, Glioma, Humans, Isocitrate Dehydrogenase, Gas Chromatography-Mass Spectrometry, Mutation, Oncogenes, Phenotype, In Situ Hybridization, Fluorescence, Disease-Free Survival, Mice, Kaplan-Meier Estimate, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
